pentoxifylline has been researched along with Endotoxemia in 18 studies
Endotoxemia: A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare effects of a single dose of pentoxifylline (PTX), flunixin meglumine (FM), and their combination (FM/PTX) in a model of equine endotoxemia." | 7.69 | Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. ( Anders, B; Barton, MH; Baskett, A; Moore, JN; Norton, N, 1997) |
| "The effective treatments of endotoxemia are necessary to prevent high mortality rates." | 5.43 | The comparative efficacy of tyloxapol versus pentoxifylline against induced acute phase response in an ovine experimental endotoxemia model. ( Badiei, K; Chalmeh, A; Heidari, SM; Nazifi, S; Pourjafar, M; Rahmani Shahraki, A; Zamiri, MJ, 2016) |
| "Pentoxifylline downregulates the inflammatory response significantly and decreases liver injury in acute endotoxemia." | 3.73 | Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. ( Coimbra, R; Hoyt, DB; Loomis, W; Melbostad, H; Porcides, RD; Tobar, M; Wolf, P, 2005) |
| " Because pentoxifylline (PTX) is known to decrease tumor necrosis factor (TNF)-alpha production and to increase anti-inflammatory cytokine synthesis, we tested the hypothesis that PTX treatment would change the pro- and anti-inflammatory balance and decrease mortality in a murine model of acute endotoxemia." | 3.73 | Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. ( Coimbra, R; Hoyt, DB; Loomis, W; Melbostad, H; Tobar, M, 2005) |
| "Although pentoxifylline (PTX) produces various beneficial effects after endotoxemia, it remains unknown whether this agent attenuates the depressed hepatocellular function and improves heart performance during early sepsis." | 3.69 | Pentoxifylline maintains hepatocellular function and improves cardiac performance during early sepsis. ( Ba, ZF; Chaudry, IH; Wang, P, 1997) |
| "To compare effects of a single dose of pentoxifylline (PTX), flunixin meglumine (FM), and their combination (FM/PTX) in a model of equine endotoxemia." | 3.69 | Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. ( Anders, B; Barton, MH; Baskett, A; Moore, JN; Norton, N, 1997) |
| "The effective treatments of endotoxemia are necessary to prevent high mortality rates." | 1.43 | The comparative efficacy of tyloxapol versus pentoxifylline against induced acute phase response in an ovine experimental endotoxemia model. ( Badiei, K; Chalmeh, A; Heidari, SM; Nazifi, S; Pourjafar, M; Rahmani Shahraki, A; Zamiri, MJ, 2016) |
| "We postulated that PTX treatment in acute endotoxemia downregulates the inflammatory response and may decrease lung injury." | 1.33 | LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression. ( Coimbra, R; Hoyt, DB; Loomis, W; Melbostad, H; Porcides, RD; Tobar, M; Wolf, P, 2006) |
| "Pentoxifylline has several functions including downregulation of TNF-alpha and endothelia-dependent vascular relaxation." | 1.33 | Pentoxifylline protects against endotoxin-induced acute renal failure in mice. ( Basava, V; Falk, S; Reznikov, L; Schrier, R; Wang, W; Zolty, E, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chłoń-Rzepa, G | 1 |
| Jankowska, A | 1 |
| Ślusarczyk, M | 1 |
| Świerczek, A | 1 |
| Pociecha, K | 1 |
| Wyska, E | 1 |
| Bucki, A | 1 |
| Gawalska, A | 1 |
| Kołaczkowski, M | 1 |
| Pawłowski, M | 1 |
| Fugler, LA | 1 |
| Eades, SC | 1 |
| Moore, RM | 1 |
| Koch, CE | 1 |
| Keowen, ML | 1 |
| Chalmeh, A | 1 |
| Rahmani Shahraki, A | 1 |
| Heidari, SM | 1 |
| Badiei, K | 1 |
| Pourjafar, M | 1 |
| Nazifi, S | 1 |
| Zamiri, MJ | 1 |
| Taha, H | 1 |
| Grochot-Przeczek, A | 1 |
| Was, H | 1 |
| Kotlinowski, J | 1 |
| Kozakowska, M | 1 |
| Marek, A | 1 |
| Skrzypek, K | 1 |
| Lackowska, B | 1 |
| Balcerczyk, A | 1 |
| Mustafa, S | 1 |
| Dulak, J | 1 |
| Jozkowicz, A | 1 |
| Motawi, TK | 1 |
| Darwish, HA | 1 |
| Abd El Tawab, AM | 1 |
| Michetti, C | 1 |
| Coimbra, R | 4 |
| Hoyt, DB | 4 |
| Loomis, W | 4 |
| Junger, W | 1 |
| Wolf, P | 3 |
| Ji, Q | 1 |
| Zhang, L | 1 |
| Jia, H | 1 |
| Xu, J | 1 |
| Porcides, RD | 2 |
| Melbostad, H | 3 |
| Tobar, M | 3 |
| Wang, W | 1 |
| Zolty, E | 1 |
| Falk, S | 1 |
| Basava, V | 1 |
| Reznikov, L | 1 |
| Schrier, R | 1 |
| Santos, AA | 1 |
| Wilmore, DW | 1 |
| Wang, P | 1 |
| Ba, ZF | 1 |
| Chaudry, IH | 1 |
| Baskett, A | 1 |
| Barton, MH | 2 |
| Norton, N | 2 |
| Anders, B | 1 |
| Moore, JN | 2 |
| Wu, CC | 1 |
| Liao, MH | 1 |
| Chen, SJ | 1 |
| Yen, MH | 1 |
| Cömert, M | 1 |
| Taneri, F | 1 |
| Tekin, E | 1 |
| Ersoy, E | 1 |
| Oktemer, S | 1 |
| Onuk, E | 1 |
| Düzgün, E | 1 |
| Ayoğlu, F | 1 |
| Jaimes, EA | 1 |
| Castillo, DD | 1 |
| Rutherford, MS | 1 |
| Raij, L | 1 |
1 trial available for pentoxifylline and Endotoxemia
| Article | Year |
|---|---|
The systemic inflammatory response: perspective of human endotoxemia.
Topics: Body Temperature; Cytokines; Endotoxemia; Endotoxins; Escherichia coli Infections; Heart Rate; Human | 1996 |
17 other studies available for pentoxifylline and Endotoxemia
| Article | Year |
|---|---|
Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanes; Cyclic Nucleotide Phosphodiesterases, Typ | 2018 |
Plasma matrix metalloproteinase activity in horses after intravenous infusion of lipopolysaccharide and treatment with matrix metalloproteinase inhibitors.
Topics: Animals; Body Temperature; Clonixin; Doxycycline; Endotoxemia; Enzyme Induction; Enzyme Inhibitors; | 2013 |
The comparative efficacy of tyloxapol versus pentoxifylline against induced acute phase response in an ovine experimental endotoxemia model.
Topics: Acute-Phase Reaction; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dose-Response Relat | 2016 |
Modulation of inflammatory response by pentoxifylline is independent of heme oxygenase-1 pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Dose-Response Relationship, Drug; Endot | 2009 |
The relative efficacy of aminoguanidine and pentoxifylline in modulating endotoxin-induced cardiac stress.
Topics: Animals; Endotoxemia; Endotoxins; Guanidines; Heart; Humans; Lipopolysaccharides; Male; Myocardium; | 2011 |
Pentoxifylline reduces acute lung injury in chronic endotoxemia.
Topics: Animals; Bronchoalveolar Lavage Fluid; CD11b Antigen; Chronic Disease; Edema; Endotoxemia; Intercell | 2003 |
Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines.
Topics: Animals; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2004 |
Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Endotoxemia; Immunohistochemistry; Inter | 2005 |
Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia.
Topics: Analysis of Variance; Animals; Cytokines; Dose-Response Relationship, Drug; Endotoxemia; Humans; In | 2005 |
LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression.
Topics: Animals; Disease Models, Animal; Endotoxemia; Escherichia coli Infections; Intercellular Adhesion Mo | 2006 |
Pentoxifylline protects against endotoxin-induced acute renal failure in mice.
Topics: Acute Kidney Injury; Alprostadil; Animals; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Down-Regu | 2006 |
Pentoxifylline maintains hepatocellular function and improves cardiac performance during early sepsis.
Topics: Animals; Cardiac Output; Endotoxemia; Heart; Indocyanine Green; Liver; Male; Pentoxifylline; Rats; R | 1997 |
Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal | 1997 |
Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Animals; Blood Pressure; Body Temperature; Disea | 1997 |
Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia.
Topics: Anesthesia; Animals; Aorta, Thoracic; Blood Circulation; Blood Pressure; Cardiovascular Diseases; Di | 1999 |
The effect of pentoxifylline on the healing of intestinal anastomosis in rats with experimental obstructive jaundice.
Topics: Anastomosis, Surgical; Animals; Cholestasis, Extrahepatic; Common Bile Duct; Endotoxemia; Enzyme Inh | 2000 |
Countervailing influence of tumor necrosis factor-alpha and nitric oxide in endotoxemia.
Topics: Analysis of Variance; Animals; Endotoxemia; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Es | 2001 |